{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:46:55Z","timestamp":1792057615937,"version":"4.4.0"},"reference-count":40,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We conducted a pharmacokinetic study to compare two fixed\u2010dose combinations of ibuprofen\/acetaminophen (IP\u2010TA and IP\u2010TB) with different formulation designs and excipient compositions, and explored how formulation differences influence ibuprofen pharmacokinetics by comparing in vitro dissolution and in vivo absorption profiles. In an open\u2010label, randomized, 2\u2010treatment, 2\u2010period, 2\u2010sequence crossover study, 24 healthy Japanese participants received a single oral dose of IP\u2010TA (ibuprofen 195\u00a0mg and acetaminophen 195\u00a0mg) or IP\u2010TB (ibuprofen 160\u00a0mg and acetaminophen 160\u00a0mg) under fasting conditions. Pharmacokinetic data were analyzed using a linear mixed\u2010effects model. Fraction absorbed (F\n                    <jats:sub>a<\/jats:sub>\n                    ) was estimated using the Loo\u2013Riegelman method, and ibuprofen dissolution was evaluated at pH 1.2, 4.0, and 6.8. The relationship between weighted mean dissolution rates (D) and F\n                    <jats:sub>a<\/jats:sub>\n                    was examined. Ibuprofen absorption from IP\u2010TA was faster than from IP\u2010TB, as reflected by higher C\n                    <jats:sub>max<\/jats:sub>\n                    and greater early exposure, and these differences remained after dose normalization. Dissolution profiles showed temporal similarity with absorption profiles, particularly for IP\u2010TA. Analysis of F\n                    <jats:sub>a<\/jats:sub>\n                    also suggested a relatively high degree of synchronization between ibuprofen and acetaminophen absorption in IP\u2010TA. These findings indicate that formulation\u2010dependent differences in dissolution behavior may influence early ibuprofen absorption, although further studies are needed to clarify the underlying mechanisms.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.70112","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:05:53Z","timestamp":1792055153000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Formulation\u2010Dependent Modulation of Ibuprofen Absorption Kinetics in Fixed\u2010Dose Combinations: An Exploratory Analysis of the Dissolution\u2013Absorption Relationship"],"prefix":"10.1002","volume":"15","author":[{"given":"Satoko","family":"Ueda","sequence":"first","affiliation":[{"name":"SSP Co., Ltd., an Opella Company  Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Chujo","sequence":"additional","affiliation":[{"name":"SSP Co., Ltd., an Opella Company  Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuo","family":"Miyadai","sequence":"additional","affiliation":[{"name":"SSP Co., Ltd., an Opella Company  Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemence","family":"Rauch","sequence":"additional","affiliation":[{"name":"Clinical and Nonclinical Development and Data Management Opella Healthcare Group SAS  Neuilly\u2010sur\u2010Seine France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine","family":"Polivka","sequence":"additional","affiliation":[{"name":"Clinical Operations GMPV Opella Healthcare Group SAS Aixial, an Alten company  Boulogne\u2010Billancourt France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Saito","sequence":"additional","affiliation":[{"name":"SSP Co., Ltd., an Opella Company  Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Kawase","sequence":"additional","affiliation":[{"name":"SSP Co., Ltd., an Opella Company  Shinjuku\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology Department of Pharmacology Showa Medical University School of Medicine  Setagaya\u2010ku Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Matsuki","sequence":"additional","affiliation":[{"name":"Clinical Research Center Medical Co. Souseikai Fukuoka Mirai Hospital  Higashi\u2010ku Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"issue":"11","key":"e_1_2_11_2_1","first-page":"832","article-title":"What are the most common conditions in primary care? Systematic review","volume":"64","author":"Finley CR","year":"2018","journal-title":"Can Fam Physician"},{"issue":"6","key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nri3843","article-title":"Fever and the thermal regulation of immunity: the immune system feels the heat","volume":"15","author":"Evans SS","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"e_1_2_11_4_1","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1172\/JCI45178","article-title":"What is this thing called pain?","volume":"120","author":"Woolf CJ","year":"2010","journal-title":"J Clin Invest"},{"issue":"4","key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik H","year":"2006","journal-title":"Eur J Pain"},{"issue":"4","key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1037\/0033-2909.133.4.581","article-title":"The biopsychosocial approach to chronic pain: scientific advances and future directions","volume":"133","author":"Gatchel RJ","year":"2007","journal-title":"Psychol Bull"},{"issue":"5","key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/ATVBAHA.110.207449","article-title":"Prostaglandins and inflammation","volume":"31","author":"Ricciotti E","year":"2011","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum AI","year":"2009","journal-title":"Cell"},{"issue":"5","key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","article-title":"The mechanism of action of aspirin","volume":"110","author":"Vane JR","year":"2003","journal-title":"Thromb Res"},{"issue":"10","key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1460-9592.2008.02764.x","article-title":"Paracetamol (Acetaminophen): mechanisms of action","volume":"18","author":"Anderson BJ","year":"2008","journal-title":"Paediatr Anaesth"},{"issue":"6","key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/00325481.2024.2382671","article-title":"Ibuprofen\/acetaminophen fixed\u2010dose combination as an alternative to opioids in management of common pain types","volume":"136","author":"Kushner P","year":"2024","journal-title":"Postgrad. Med."},{"issue":"1","key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40263-020-00777-7","article-title":"Efficacy and safety of ibuprofen plus paracetamol in a fixed\u2010dose combination for acute postoperative pain in adults: meta\u2010analysis and a trial sequential analysis","volume":"35","author":"Abushanab D","year":"2021","journal-title":"CNS Drugs"},{"key":"e_1_2_11_13_1","first-page":"73","article-title":"Comparative pharmacokinetics of two fast\u2010dissolving oral ibuprofen formulations and a regular\u2010release ibuprofen tablet in healthy volunteers","volume":"21","author":"Schettler T","year":"2001","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1016\/j.xphs.2015.12.019","article-title":"Review of disintegrants and the disintegration phenomena","volume":"105","author":"Desai PM","year":"2016","journal-title":"J Pharm Sci"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jddst.2019.02.027","article-title":"In\u2010vivo disintegration and absorption of two fast acting aspirin tablet formulations compared to ibuprofen tablets using pharmacoscintigraphy","volume":"51","author":"Stevens H","year":"2019","journal-title":"J Drug Deliv Sci Technol"},{"issue":"5","key":"e_1_2_11_16_1","first-page":"329","article-title":"Development of fast dissoluble ibuprofen tablet","volume":"69","author":"Kawase I","year":"2009","journal-title":"J. Pharma. Sci. Tech."},{"key":"e_1_2_11_17_1","unstructured":"Lion Corporation. Bufferin Premium DX+. Accessed June 22 2026.https:\/\/www.bufferin.net\/products\/premiumdx."},{"issue":"4","key":"e_1_2_11_18_1","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s13318-022-00766-9","article-title":"Population pharmacokinetic modelling of acetaminophen and ibuprofen: the influence of body composition, formulation and feeding in healthy adult volunteers","volume":"47","author":"Morse JD","year":"2022","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1472-6904-9-19","article-title":"Bioavailability of ibuprofen following oral administration of standard ibuprofen, sodium ibuprofen or ibuprofen acid","volume":"9","author":"Dewland PM","year":"2009","journal-title":"BMC Clin. Pharmacol."},{"issue":"1","key":"e_1_2_11_20_1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1208\/s12248-025-01016-x","article-title":"Gastrointestinal bile salt concentrations in healthy adults under fasted and fed conditions: a systematic review and meta\u2010analysis for mechanistic physiologically\u2010based pharmacokinetic (PBPK) modelling","volume":"27","author":"Santos LGA","year":"2025","journal-title":"AAPS J"},{"issue":"3","key":"e_1_2_11_21_1","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1055\/a-1073-7653","article-title":"Defining gastrointestinal transit time using video capsule endoscopy: a study of healthy subjects","volume":"8","author":"O'Grady J","year":"2020","journal-title":"Endosc Int Open"},{"key":"e_1_2_11_22_1","volume-title":"Bioavailability Studies Submitted in NDAs or INDs\u2014General Considerations. Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2022"},{"issue":"9","key":"e_1_2_11_23_1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/art.1780270918","article-title":"Absorption and disposition of ibuprofen in the elderly","volume":"27","author":"Greenblatt DJ","year":"1984","journal-title":"Arthritis Rheum"},{"issue":"2","key":"e_1_2_11_24_1","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00003088-198207020-00001","article-title":"Clinical pharmacokinetics of paracetamol","volume":"7","author":"Forrest JA","year":"1982","journal-title":"Clin. Pharmacokinet."},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1472-6904-10-10","article-title":"The pharmacokinetic profile of a novel fixed\u2010dose combination tablet of ibuprofen and paracetamol","volume":"10","author":"Tanner T","year":"2010","journal-title":"BMC Clin. Pharmacol."},{"issue":"10","key":"e_1_2_11_26_1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40261-015-0320-8","article-title":"Pharmacokinetics and bioavailability of a fixed\u2010dose combination of ibuprofen and paracetamol after intravenous and oral administration","volume":"35","author":"Atkinson HC","year":"2015","journal-title":"Clin. Drug Investig."},{"issue":"6","key":"e_1_2_11_27_1","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1002\/cpdd.672","article-title":"Pharmacokinetic properties of ibuprofen (IBU) from the fixed\u2010dose combination IBU\/caffeine (400\/100\u00a0mg; FDC) in comparison with 400\u00a0mg IBU as acid or lysinate under fasted and fed conditions\u2010data from 2 single\u2010center, single\u2010dose, randomized crossover studies in healthy volunteers","volume":"8","author":"Weiser T","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"2","key":"e_1_2_11_28_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg M","year":"2004","journal-title":"Eur J Pharm Biopharm"},{"key":"e_1_2_11_29_1","article-title":"Drug solubility: importance and enhancement techniques","volume":"2012","author":"Savjani KT","year":"2012","journal-title":"ISRN Pharm"},{"issue":"1","key":"e_1_2_11_30_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2011.01.007","article-title":"State of the art of nanocrystals\u2013special features, production, nanotoxicology aspects and intracellular delivery","volume":"78","author":"M\u00fcller RH","year":"2011","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"e_1_2_11_31_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug\u2010like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski CA","year":"2000","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"6","key":"e_1_2_11_32_1","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/ci600292q","article-title":"Prediction of pH\u2010dependent aqueous solubility of druglike molecules","volume":"46","author":"Hansen NT","year":"2006","journal-title":"J Chem Inf Model"},{"issue":"3","key":"e_1_2_11_33_1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1365-2125.1991.tb05527.x","article-title":"The effect of magnesium hydroxide on the oral absorption of ibuprofen, ketoprofen and diclofenac","volume":"31","author":"Neuvonen PJ","year":"1991","journal-title":"Br J Clin Pharmacol"},{"issue":"12","key":"e_1_2_11_34_1","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1248\/yakushi.127.2085","article-title":"The quality evaluation of magnesium oxide tablets using acid neutralization test and dissolution test","volume":"127","author":"Inoue C","year":"2007","journal-title":"Yakugaku Zasshi"},{"issue":"6","key":"e_1_2_11_35_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1248\/yakushi.125.525","article-title":"The quality evaluation of magnesium oxide tablet due to acid neutralization action","volume":"125","author":"Hamaguchi T","year":"2005","journal-title":"Yakugaku Zasshi"},{"key":"e_1_2_11_36_1","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1080\/03639040801901868","article-title":"Physicochemical characterization of interaction of ibuprofen by solid\u2010state milling with aluminum hydroxide","volume":"34","author":"Mallick S","year":"2008","journal-title":"Drug Dev Ind Pharm"},{"issue":"5853","key":"e_1_2_11_37_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bmj.1.5853.587","article-title":"Pharmacological modification of gastric emptying: effects of propantheline and metoclopromide on paracetamol absorption","volume":"1","author":"Nimmo J","year":"1973","journal-title":"Br Med J"},{"issue":"2","key":"e_1_2_11_38_1","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1476-5381.1973.tb08339.x","article-title":"The dependence of paracetamol absorption on the rate of gastric emptying","volume":"47","author":"Heading RC","year":"1973","journal-title":"Br J Pharmacol"},{"issue":"2","key":"e_1_2_11_39_1","doi-asserted-by":"crossref","first-page":"178","DOI":"10.3390\/pharmaceutics16020178","article-title":"Fixed\u2010dose combination formulations in solid oral drug therapy: advantages, limitations, and design features","volume":"16","author":"Wilkins CA","year":"2024","journal-title":"Pharmaceutics"},{"key":"e_1_2_11_40_1","unstructured":"European Medicines Agency.Guideline on clinical development of fixed combination medicinal products. Legal effective date: October 1 2017.https:\/\/www.ema.europa.eu\/en\/clinical\u2010development\u2010fixed\u2010combination\u2010medicinal\u2010products\u2010scientific\u2010guideline"},{"issue":"1","key":"e_1_2_11_41_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s40268-020-00293-5","article-title":"Phase I pharmacokinetic study of fixed\u2010dose combinations of ibuprofen and acetaminophen in healthy adult and adolescent populations","volume":"20","author":"Tarabar S","year":"2020","journal-title":"Drugs R D"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70112","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.70112","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.70112","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:06:04Z","timestamp":1792055164000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.70112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1002\/cpdd.70112"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.70112","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"2026-06-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-10-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70112"}}